Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 2:02 pm Purchase |
2023-12-31 | 13G | Neurogene Inc. NGNE |
JANUS HENDERSON GROUP PLC JHG |
841,688 6.600% |
841,688 (New Position) |
Filing History |
| 2024-02-14 09:19 am Sale |
2023-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Lynx1 Capital Management LP | 46 0.100% |
-114,511 (-99.96%) |
Filing History |
| 2023-12-27 4:03 pm Purchase |
2023-12-18 | 13G | Neurogene Inc. NGNE |
Great Point Partners, LLC | 969,229 7.560% |
969,229 (New Position) |
Filing History |
| 2023-12-22 4:15 pm Purchase |
2023-12-18 | 13G | Neurogene Inc. NGNE |
Redmile Group LLC | 1,282,661 9.900% |
1,282,661 (New Position) |
Filing History |
| 2023-12-21 4:05 pm Purchase |
2023-12-18 | 13D | Neurogene Inc. NGNE |
McMinn Rachel | 1,273,351 9.900% |
1,273,351 (New Position) |
Filing History |
| 2023-12-20 5:24 pm Purchase |
2023-12-18 | 13D | Neurogene Inc. NGNE |
Baker Bros. Advisors LP | 649,685 4.990% |
649,685 (New Position) |
Filing History |
| 2023-10-10 4:42 pm Purchase |
2023-10-05 | 13D | Neoleukin Therapeutics, Inc. NLTX |
Baker Bros. Advisors LP | 473,667 19.990% |
473,667 (New Position) |
Filing History |
| 2023-08-17 5:12 pm Sale |
2023-08-15 | 13D | Neoleukin Therapeutics, Inc. NLTX |
Baker Bros. Advisors LP | 473,605 19.990% |
-28,549 (-5.69%) |
Filing History |
| 2023-07-27 5:15 pm Sale |
2023-07-17 | 13D | Neoleukin Therapeutics, Inc. NLTX |
Redmile Group LLC | 145,611 6.600% |
-5,917 (-3.90%) |
Filing History |
| 2023-07-19 5:28 pm Purchase |
2023-07-17 | 13D | Neoleukin Therapeutics, Inc. NLTX |
Baker Bros. Advisors LP | 502,154 19.990% |
290,663 (+137.43%) |
Filing History |
| 2023-02-14 4:21 pm Sale |
2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Redmile Group LLC | 151,528 6.900% |
-64,550 (-29.87%) |
Filing History |
| 2023-02-03 11:56 am Sale |
2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
PICTET ASSET MANAGEMENT SA | 0 0.000% |
-128,714 (Position Closed) |
Filing History |
| 2023-01-19 4:10 pm Sale |
2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Integrated Core Strategies (US) LLC | 79,363 3.700% |
-27,266 (-25.57%) |
Filing History |
| 2022-12-30 4:29 pm Purchase |
2022-12-20 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Lynx1 Capital Management LP | 114,557 5.380% |
114,557 (New Position) |
Filing History |
| 2022-07-19 4:08 pm Purchase |
2022-07-18 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Integrated Core Strategies (US) LLC | 106,629 5.000% |
1,058 (+1.00%) |
Filing History |
| 2022-07-15 4:04 pm Sale |
2022-07-07 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Integrated Core Strategies (US) LLC | 105,571 4.970% |
-269 (-0.25%) |
Filing History |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Neoleukin Therapeutics, Inc. NLTX |
BlackRock Inc. BLK |
45,542 2.100% |
-84,691 (-65.03%) |
Filing History |
| 2022-07-07 4:56 pm Purchase |
2022-06-27 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Integrated Core Strategies (US) LLC | 105,840 4.980% |
105,840 (New Position) |
Filing History |
| 2022-02-14 5:07 pm Purchase |
2021-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Redmile Group LLC | 216,078 9.900% |
6,295 (+3.00%) |
Filing History |
| 2022-02-14 3:03 pm Sale |
2021-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
EcoR1 Capital LLC | 43,031 2.000% |
-113,104 (-72.44%) |
Filing History |